Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Chinese Journal of Applied Physiology ; (6): 32-36, 2022.
Article Dans Chinois | WPRIM | ID: wpr-927893

Résumé

Objective: To investigate the effects of glycogen synthase kinase-3β (GSK3β)/eukaryotic extension factor kinase 2 (eEF2K) signaling pathway on the process of pulmonary fibrosis through in vivo experiments, and find new ideas for clinical treatment of pulmonary fibrosis. Methods: The pulmonary fibrosis model of C57BL/6 male mice was induced by bleomycin with intratracheal injection at the dose of 2 mg/kg. After 14 days of modeling, animals were divided into model group, negative inhibition group and inhibition group (n=5 for each group), and control group was not processed. The inhibition group was treated with TDZD-8 (4 mg/kg) after modeling, the negative inhibition group was given DMSO solution after modeling, and the samples were collected after 28 days. Hematoxylin-eosin staining method was used to detect lung fibrosis in mice and scored according to Ashcroft scale. Expression levels of GSK3β, p-GSK3β, eEF2K, p-eEF2K (Ser70, Ser392, Ser470), precursor protein of matrix metalloproteinase-2 (pro-MMP-2), matrix metalloproteinase-2 (MMP-2), collagen I (Col I), collagen Ⅲ (Col Ⅲ) and α-smooth muscle actin (α-SMA) were detected by Western blot. Results: Compared with control group, the fibrosis score was up-regulated, the expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were increased, while that of eEF2K was decreased in model group (P<0.05). Compared with model group, the fibrosis score, expression levels of GSK3β, p-GSK3β, p-eEF2K (Ser70, Ser392, Ser470), pro-MMP-2, MMP-2, Col I, Col Ⅲ and α-SMA were decreased, but the expression level of eEF2K was increased in inhibition group (P<0.05). Conclusion: GSK3β can activate eEF2K by phosphorylation at the sites of Ser70, Ser392 and Ser470, increase the contents of fibrosis indicators, promote the formation of pulmonary fibrosis, and aggravate lung tissue lesions.


Sujets)
Animaux , Mâle , Souris , Collagène , Collagène de type I , Elongation Factor 2 Kinase/métabolisme , Eucaryotes/métabolisme , Fibrose , Glycogen synthase kinase 3 beta , Matrix metalloproteinase 2/métabolisme , Souris de lignée C57BL , Fibrose pulmonaire/induit chimiquement , Transduction du signal
2.
Experimental & Molecular Medicine ; : 550-560, 2011.
Article Dans Anglais | WPRIM | ID: wpr-131300

Résumé

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Sujets)
Animaux , Souris , Arginine , Dédifférenciation cellulaire , Inhibiteur p21 de kinase cycline-dépendante/génétique , Elongation Factor 2 Kinase/métabolisme , Facteur de croissance fibroblastique de type 2/métabolisme , Fibroblastes/métabolisme , Flavonoïdes/pharmacologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Méthylation , Mitogen-Activated Protein Kinases/antagonistes et inhibiteurs , Myofibroblastes/anatomopathologie , Cellules NIH 3T3 , Protein Methyltransferases/métabolisme , Protein-arginine N-methyltransferases/métabolisme , Petit ARN interférent/génétique
3.
Experimental & Molecular Medicine ; : 550-560, 2011.
Article Dans Anglais | WPRIM | ID: wpr-131297

Résumé

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Sujets)
Animaux , Souris , Arginine , Dédifférenciation cellulaire , Inhibiteur p21 de kinase cycline-dépendante/génétique , Elongation Factor 2 Kinase/métabolisme , Facteur de croissance fibroblastique de type 2/métabolisme , Fibroblastes/métabolisme , Flavonoïdes/pharmacologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Méthylation , Mitogen-Activated Protein Kinases/antagonistes et inhibiteurs , Myofibroblastes/anatomopathologie , Cellules NIH 3T3 , Protein Methyltransferases/métabolisme , Protein-arginine N-methyltransferases/métabolisme , Petit ARN interférent/génétique
SÉLECTION CITATIONS
Détails de la recherche